Fig. 6

Frequency of relapse (times/year) from the start of conventional treatment to 1 year before mepolizumab administration, within the year before mepolizumab initiation, and by year until the final visit in the super-responder group (squares) and the responder group (circles). Mean values for responder and super-responder groups were compared by using the Wilcoxon matched-pairs t-test; p < 0.05 (*) was considered statistically significant. †p < 0.01. Upper brackets at the top show the significance of differences between the start of conventional treatment versus 1 year before initiation of mepolizumab treatment, the time of initiation of mepolizumab treatment, and years 1, 2, 3, and last examination during mepolizumab treatment in the responder group; middle brackets show the significance of differences between the start of conventional treatment versus 1 year before initiation of mepolizumab treatment, the time of initiation of mepolizumab treatment, and years 1, 2, 3, and last examination during mepolizumab treatment in the super-responder group; lower brackets show the significance of differences between 1 year after initiation of mepolizumab and years 2 and 3 and last examination during mepolizumab treatment in the super-responder group